Mark Davis
MD
Warren and Katharine Schlinger Professor
👥Biography 个人简介
Mark Davis at Caltech developed cyclodextrin-based nanoparticles (CALAA-01) for targeted siRNA delivery — the first nanoparticle-delivered siRNA construct to enter human clinical trials. His demonstration of siRNA tumor delivery in humans using transferrin-targeted CALAA-01 particles established proof of mechanism for targeted RNAi in cancer. His contributions to polymer chemistry and nanoparticle design have advanced the cancer nanomedicine field.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Mark Davis 的研究动态
Follow Mark Davis's research updates
留下邮箱，当我们发布与 Mark Davis（California Institute of Technology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment